Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Delbart

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Seminars in Nuclear Medicine|September 23, 2025
Expanding the Horizon of Targeted Radionuclide Therapy: Immunotherapy Combinations and FAP-Targeted ApproachesAyça Arçay Öztürk, Wendy Delbart, Patrick Flamen
Nuclear Medicine and Biology|April 11, 2021
Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [<sup>177</sup>Lu]Lu-DOTATATE in a panel of cancer cell linesWendy Delbart, Ghanem E Ghanem, Ioannis Karfis, et al.
European Journal of Hybrid Imaging|April 19, 2022
Suspicious cold thyroid nodule with intense focal 68Ga-DOTATATE uptake: a case reportRingo Manta, Wendy Delbart, Ivan Duran Derijckere, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 28, 2026
Toward Personalized Radiopharmaceutical Therapy: Radiobiologic Insights Compared with External-Beam RadiotherapySébastien Penninckx, Wendy Delbart, Magdalena Mileva, et al.
International Journal of Molecular Sciences|October 27, 2022
Understanding the Radiobiological Mechanisms Induced by <sup>177</sup>Lu-DOTATATE in Comparison to External Beam Radiation TherapyWendy Delbart, Jirair Karabet, Gwennaëlle Marin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 27, 2025
The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myelomaWendy Delbart, Ioannis Karfis, Marie Vercruyssen, et al.
EJNMMI Reports|July 27, 2025
First-in-human experience of radiopharmaceutical therapy with [<sup>177</sup>Lu]Lu-DOTATATE in patients with advanced multiple myelomaWendy Delbart, Marie Vercruyssen, Rachele Danieli, et al.
EJNMMI Research|November 18, 2024
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN studyRachele Danieli, Magdalena Mileva, Gwennaëlle Marin, et al.
Cancers|May 16, 2023
Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATEWendy Delbart, Gwennaëlle Marin, Basile Stamatopoulos, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Seminars in Nuclear Medicine|September 23, 2025
Expanding the Horizon of Targeted Radionuclide Therapy: Immunotherapy Combinations and FAP-Targeted ApproachesAyça Arçay Öztürk, Wendy Delbart, Patrick Flamen
Nuclear Medicine and Biology|April 11, 2021
Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [<sup>177</sup>Lu]Lu-DOTATATE in a panel of cancer cell linesWendy Delbart, Ghanem E Ghanem, Ioannis Karfis, et al.
European Journal of Hybrid Imaging|April 19, 2022
Suspicious cold thyroid nodule with intense focal 68Ga-DOTATATE uptake: a case reportRingo Manta, Wendy Delbart, Ivan Duran Derijckere, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 28, 2026
Toward Personalized Radiopharmaceutical Therapy: Radiobiologic Insights Compared with External-Beam RadiotherapySébastien Penninckx, Wendy Delbart, Magdalena Mileva, et al.
International Journal of Molecular Sciences|October 27, 2022
Understanding the Radiobiological Mechanisms Induced by <sup>177</sup>Lu-DOTATATE in Comparison to External Beam Radiation TherapyWendy Delbart, Jirair Karabet, Gwennaëlle Marin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 27, 2025
The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myelomaWendy Delbart, Ioannis Karfis, Marie Vercruyssen, et al.
EJNMMI Reports|July 27, 2025
First-in-human experience of radiopharmaceutical therapy with [<sup>177</sup>Lu]Lu-DOTATATE in patients with advanced multiple myelomaWendy Delbart, Marie Vercruyssen, Rachele Danieli, et al.
EJNMMI Research|November 18, 2024
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN studyRachele Danieli, Magdalena Mileva, Gwennaëlle Marin, et al.
Cancers|May 16, 2023
Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATEWendy Delbart, Gwennaëlle Marin, Basile Stamatopoulos, et al.
Pageof 1